BioSpace News Archive

Synthetic Biologics, Inc. (NYSE American: SYN), announced today that Steven A. Shallcross, Chief Executive and Financial Officer, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 10, 2020, at 11:00 a.m. (ET) at the New York Marriott Marquis (Wilder room).

Plex Pharmaceuticals, Inc. (“Plex”), today announced it has been awarded a $600,000 Phase I Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to develop novel antiviral drug candidate(s) for the treatment of Dengue (DENV) fever, West Nile Virus (WNV) and Zika Virus (ZKV) infections.

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, Chief Financial Officer, will present a corporate overview at the 22nd Annual BIO CEO & Investor Conference, being held in New York City on February 10-11, 2020.

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), today announced that Stefan Weber, CEO, will present at the 22nd Annual BIO CEO & Investor Conference in New York, NY on Tuesday, February 11, 2020 at 11:00 a.m. ET in the Odets room (4th floor) at the New York Marriott Marquis.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2019.

Globus Medical, Inc., a leading musculoskeletal solutions company announced Dr. Joshua S. Rovner became the first spine surgeon to implant HEDRON IA, a 3D printed integrated ALIF spacer that leverages anchors or screws for vertebral body fixation.

DENTSPLY SIRONA Inc., The Dental Solutions Company™, announced that the Company will host an investor conference call and live webcast on Monday, March 2, 2020 at 8:30 am ET and send out an earnings press release earlier that morning.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock.

Kezar Life Sciences, Inc. announced the closing of an underwritten public offering of 16,115,385 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 2,884,615 shares of its common stock at an exercise price of $0.001 per share.

The 3M Board of Directors declared a dividend on the company’s common stock of $1.47 per share for the first quarter of 2020, an increase of 2 percent over the quarterly dividend paid in 2019.